HOSPITAL UNIVERSITARIO RUBER
Departamento
Hospital Ruber Internacional
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ruber Internacional (7)
2024
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
-
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
ESMO Open, Vol. 9, Núm. 9
2023
-
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Neuro-Oncology, Vol. 25, Núm. 1, pp. 157-166
2022
-
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
International Journal of Infectious Diseases, Vol. 123, pp. 97-103
2020
-
The persistent breach between evidence and practice in the prevention of surgical site infection. Qualitative study
International Journal of Surgery
2019
-
Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm
Current Breast Cancer Reports, Vol. 11, Núm. 4, pp. 248-258
2018
-
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer
Annals of Oncology, Vol. 29, Núm. 4, pp. 881-887